EDGE MEDICAL-B

2675
26.3203.73% ( -1.020 )
Delay Closed: Nov 16, 16:08:11

Overview

EDGE MEDICAL-B (2675)

Shenzhen Edge Medical Co., Ltd. engages in designing, developing, manufacturing, and sale of surgical robots in Europe, and China. The company focus on surgical...

Open
27.180
High
27.180
Low
26.180
Prev. Close
27.340
Volume
117.40K
Turnover
3.11M
Avg Price
26.480
Bid/Ask Ratio
46.67%
Amplitude
3.66%
52wk High
73.700
Volume Ratio
0.34
Turnover Ratio
0.04%
52wk Low
25.380
HK Mkt Cap
8.50B
Market CapHKD
10.19B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.0558
EPSDynamic
-0.114
EPSStatic
--
BVPS
6.87
P/B
3.83
HK Shares
323.12M
Dividend YieldTTM
--
DividendTTM
--
Shares
387.24M
Min lot size
100
Currency
HKD

EDGE MEDICAL-B Analyst Rating

View more

Forecast & Rating

Nov 13, 2026
Price forecast
HK$53.14101.89%
Forecast & RatingStrong buy
5analysts
  • Strong buy60.00%
  • Buy40.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 13

    Edge Medical-B fell about 1.9% to HK$27.34 in a spike-and-fade session: it opened at HK$27.22, briefly touched HK$27.36, then slid to an intraday HK$26.22 in the afternoon, with only 399,600 shares and roughly HK$10.6 million of turnover, a 0.12% turnover rate that magnified the move. The stock had already lost 13.47% over the prior week and printed a 52-week low of HK$25.38, so sentiment remains unrepaired. Fundamentals cut against the tape: Q2 2026 revenue reached HK$184.4 million, up 125.32% year on year, operating profit HK$14.4 million (+125.31%), and the net loss narrowed 77.22% to HK$11.1 million, with EPS of -HK$0.0285 improving 78.96%; yet net margin is still -6.03%, ROE -1.67%, PE negative and PB 3.98, so profitability has not turned positive. At HK$27.34 the shares sit 62.9% below the HK$73.7 52-week high, down 51.7% year to date, and beneath both MA20 (HK$29.75) and MA60 (HK$33.16). Repeated HKEX share-buyback disclosures and a Singapore surgical-robot rollout offer some support, though the repurchases look modest against a HK$10.59 billion market cap.

  2. Nov, 10

    Edge Medical-B rose 3.4% to HK$28.14, supported by persistent buybacks after the stock touched a 52-week low of HK$25.38 on November 3; it repurchased 200,000 shares for HK$5.8979 million that day and has disclosed repurchases almost daily since late October. The intraday shape was a spike-and-fade: the session high of HK$28.64 came at 09:32 BJ, price slid to HK$27.84 by 11:42, then ranged between HK$27.86 and HK$28.24 through the afternoon and settled near HK$28.00 on HK$4.32 million turnover. Fundamentals contrast with the tape: Q2 2026 revenue of HK$184.4 million grew 125.32% year on year and the net loss narrowed to HK$11.12 million, a 77.22% improvement, yet the shares remain down 50.28% year to date, 61.82% below the January 14 high of HK$73.7, and under both the MA20 of HK$30.41 and MA60 of HK$33.62. Though turnover rate was just 0.05% and trading thin, leaving the durability of the rebound unclear.

  3. Nov, 6

    Edge Medical-B reversed an early gain to close down 4.63% at HK$26.34, having touched HK$27.16 at 10:35 BJ before sliding to an intraday low of HK$26.12 at 14:12 BJ on 317,982 shares worth roughly HK$8.46 million. The move extends the weakness that carried the stock to a 52-week low of HK$25.38 on Nov 3, and buybacks running since late October — 200,000 shares for HK$5.8979 million on Nov 3 alone, after 300,000 shares for HK$9.991 million on Oct 28 — have not steadied the price. Fundamentals cut the other way: Q2 2026 revenue hit HK$184.4 million, up 125.32% year on year, operating profit reached HK$14.4 million, up 125.31%, and the net loss narrowed 77.22% to HK$11.1 million. Against that, the quote sits below its MA20 of HK$30.94 and MA60 of HK$34.00, down 53.46% year to date, 64.26% below the 52-week high of HK$73.7 and only 3.78% above the 52-week low, with a price-to-book of 3.84. Trading remains thin, though, with a turnover rate of just 0.10%.

  4. Nov, 5

    Edge Medical-B (2675.HK) spiked and then faded, touching HK$29.28 in the morning session before sliding to HK$27.08 in the afternoon and closing at HK$27.62, down 0.93% on about HK$11.98 million turnover and a 0.13% turnover rate; having set a 52-week low of HK$25.38 on November 3, the stock attracted little follow-through buying even as the company repurchased another 200,000 shares for HK$5.8979 million that day. The gap with fundamentals is wide: Q2 2026 revenue reached HK$184.41 million, up 125.32% year on year, operating profit was HK$14.40 million and the net loss narrowed to HK$11.12 million, a 77.22% improvement, yet the shares are down 51.2% year to date, 62.52% below the January 14 high of HK$73.70 and under both MA20 of HK$31.27 and MA60 of HK$34.23, with price-to-book at 4.02x. Buybacks have run repeatedly since late October, including 300,000 shares on October 28 and 217,600 on October 22, though thin daily liquidity still limits how fast earnings progress feeds into pricing.

  5. Nov, 4

    Edge Medical-B reversed off its lows but still closed down 1.13% at HK$27.88, as afternoon buying pulled the stock back from a 52-week low of HK$25.38 hit at 11:53 in the morning session; it had opened at HK$28.20 and touched HK$28.30 at 09:31 before sliding, and finished at HK$28.00 on 1.99 million shares and HK$52.9 million turnover. The afternoon recovery tracked a steady buyback run: 200,000 shares for HK$5.90 million on 3 November and 300,000 shares for HK$9.99 million on 28 October. Q2 2026 revenue rose 125.32% year on year to HK$184.4 million with operating profit of HK$14.4 million, narrowing the net loss 77.22% to HK$11.1 million, yet the shares remain down 50.74% YTD, 62.17% below the HK$73.70 52-week high and under both the MA20 of HK$31.54 and MA60 of HK$34.44, at 4.06x book. Though single buybacks of HK$2-10 million stay small against a HK$10.8 billion market cap.

News